close
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Allogene Therapeutics, Inc. - Common Stock (NQ:ALLO)

2.055 -0.055 (-2.61%)
Streaming Delayed Price Updated: 3:01 PM EDT, Jul 2, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 6,805,957
Open 2.130
Bid (Size) 2.050 (37,900)
Ask (Size) 2.060 (103,600)
Prev. Close 2.110
Today's Range 2.030 - 2.180
52wk Range 0.9842 - 4.460
Shares Outstanding 142,183,418
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Allogene Therapeutics Announces Planned CEO Succession
From Allogene Therapeutics, Inc.
Via GlobeNewswire
News headline image
Allogene Therapeutics Announces Participation in Upcoming Investor Conferences
From Allogene Therapeutics, Inc.
Via GlobeNewswire

Performance

YTD
+52.2%
+52.2%
1 Month
-4.4%
-4.4%
3 Month
-19.7%
-19.7%
6 Month
+50.0%
+50.0%
1 Year
+74.2%
+74.2%

More News

Read More
News headline image
Allogene Therapeutics Q1 Earnings Call Highlights ↗
Via MarketBeat
Topics Earnings
News headline image
Allogene (ALLO) Q1 2026 Earnings Transcript ↗
Via The Motley Fool
News headline image
Allogene Therapeutics Q1 2026 Earnings Call Transcript ↗
Via Benzinga
Topics Earnings
News headline image
Allogene Therapeutics Reports First Quarter 2026 Financial Results and Business Update
From Allogene Therapeutics, Inc.
Via GlobeNewswire
News headline image
Allogene Therapeutics to Report First Quarter Financial Results and Provide Business Update
From Allogene Therapeutics, Inc.
Via GlobeNewswire
News headline image
Allogene Therapeutics Expands Pivotal Phase 2 ALPHA3 Trial to South Korea and Australia
From Allogene Therapeutics, Inc.
Via GlobeNewswire
News headline image
Allogene Therapeutics Showcases Momentum with Clinical and Platform Advancements in Allogeneic CAR T at AACR 2026
From Allogene Therapeutics, Inc.
Via GlobeNewswire
News headline image
Allogene Therapeutics Announces Closing of $200.4 Million Public Offering of Common Stock
From Allogene Therapeutics, Inc.
Via GlobeNewswire
Thursday's session: gap up and gap down stocks ↗
Via Chartmill
News headline image
Allogene Therapeutics Announces Nature Communications Publication Highlighting Pre-Clinical Data for ALLO-329, a Next Generation Dual-Targeted CD19/CD70 Allogeneic CAR T for Autoimmune Diseases
From Allogene Therapeutics, Inc.
Via GlobeNewswire
News headline image
Allogene Therapeutics Announces Pricing of Public Offering of Common Stock
From Allogene Therapeutics, Inc.
Via GlobeNewswire
News headline image
JPMorgan, Allogene Therapeutics And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session ↗
Via Benzinga
News headline image
Allogene Therapeutics Announces Proposed Public Offering of $175 Million of Common Stock
From Allogene Therapeutics, Inc.
Via GlobeNewswire
News headline image
These stocks are making the most noise in today's session. ↗
Via Chartmill
News headline image
ENDRA Life Sciences (NASDAQ: NDRA) Targets Billions With TAEUS® Liver Imaging Technology
Via AB Newswire
News headline image
Allogene Therapeutics Stock Hits 52-Week High - Here's Why ↗
Via Benzinga
News headline image
These stocks are gapping in today's session ↗
Via Chartmill
News headline image
Leggett & Platt, Allogene Therapeutics, Revolution Medicines And Other Big Stocks Moving Higher On Monday ↗
Via Benzinga
Topics Stocks
News headline image
Which stocks are moving before the opening bell on Monday? ↗
Via Chartmill
News headline image
Allogene Therapeutics Reports Interim Futility Analysis from Pivotal ALPHA3 Trial Showing 58.3% MRD Clearance with Cemacabtagene Ansegedleucel (Cema-Cel) vs. 16.7% in Observation Arm in First-Line Consolidation LBCL
From Allogene Therapeutics, Inc.
Via GlobeNewswire
News headline image
Get insights into the top gainers and losers of Friday's after-hours session. ↗
Via Chartmill
News headline image
Allogene Therapeutics to Announce Interim Futility Analysis Data from its Pivotal Phase 2 ALPHA3 Trial with Cemacabtagene Ansegedleucel (Cema-Cel) in First-Line Consolidation LBCL on Monday, April 13, 2026
From Allogene Therapeutics, Inc.
Via GlobeNewswire
News headline image
Allogene (ALLO) Q4 2025 Earnings Call Transcript ↗
Via The Motley Fool
Topics Earnings

Frequently Asked Questions

Is Allogene Therapeutics, Inc. - Common Stock publicly traded?
Yes, Allogene Therapeutics, Inc. - Common Stock is publicly traded.
What exchange does Allogene Therapeutics, Inc. - Common Stock trade on?
Allogene Therapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Allogene Therapeutics, Inc. - Common Stock?
The ticker symbol for Allogene Therapeutics, Inc. - Common Stock is ALLO on the Nasdaq Stock Market
What is the current price of Allogene Therapeutics, Inc. - Common Stock?
The current price of Allogene Therapeutics, Inc. - Common Stock is 2.055
When was Allogene Therapeutics, Inc. - Common Stock last traded?
The last trade of Allogene Therapeutics, Inc. - Common Stock was at 07/02/26 03:01 PM ET
What is the market capitalization of Allogene Therapeutics, Inc. - Common Stock?
The market capitalization of Allogene Therapeutics, Inc. - Common Stock is 292.19M
How many shares of Allogene Therapeutics, Inc. - Common Stock are outstanding?
Allogene Therapeutics, Inc. - Common Stock has 292M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Starting at $3.75/week.

Subscribe Today